Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Shasqi
AddedFeb 17, 2024
UpdatedJun 18, 2026
Shasqi

Shasqi

Shasqi: Innovating cancer treatment with click chemistry for targeted therapy.

HQ
San Francisco, CA, US
Founded
2015
Accelerator
Y Combinator logoY CombinatorW15
Overview
Compare
Fundraising
Employees
Website

Founded with the mission to revolutionize cancer treatment, Shasqi leverages click chemistry to deliver targeted therapies directly to tumors. Utilizing its proprietary CAPAC™ platform, Shasqi's technology localizes a click chemistry reagent in the tumor area, which activates a systemically infused protodrug upon interaction. This innovative approach ensures powerful localized therapy while minimizing systemic toxicity. Shasqi focuses on developing advanced cancer therapeutics, aiming to significantly improve patient outcomes.

Notable figures affiliated with Shasqi include experts in oncology and medicinal chemistry, who contribute to the company's pioneering efforts. Key investors support the company's groundbreaking research and development. Among its achievements, Shasqi has presented promising Phase 2a results of its SQ3370 therapeutic at major conferences like ASCO and AACR. The company's impact lies in its potential to transform cancer treatment paradigms, offering more effective and safer options for patients worldwide.

Shasqi - Similar Companies

Asher Bio logo

Asher Bio

asherbio.com

Alixia logo

Alixia

alixia.com

BloodQ logo

BloodQ

bloodq.com

Palm Therapeutics logo

Palm Therapeutics

Novasenta logo

Novasenta

novasenta.com

Quanta Therapeutics logo

Quanta Therapeutics

quantatx.com

Camino Pharma logo

Camino Pharma

caminopharma.com

Qrono logo

Qrono

qrono.com

Serinus Biosciences logo

Serinus Biosciences

serinus.bio

Eris Biotech logo

Eris Biotech

erisbio.com

Cancervax logo

Cancervax

cancervax.com

SEngine Precision Medicine logo

SEngine Precision Medicine

Sus Clinicals logo

Sus Clinicals

susclinicals.com

KSQ Therapeutics logo

KSQ Therapeutics

ksqtx.com

Yosemite logo

Yosemite

yosemite.co

Shasqi - Quick Facts

Who are Shasqi's competitors?

Companies similar to Shasqi include Asher Bio, Alixia, BloodQ and Palm Therapeutics.

When was Shasqi founded?

Shasqi was founded in 2015.

Where is Shasqi's headquarters located?

Shasqi's headquarters is located in San Francisco, CA, US.

When was Shasqi's last funding round?

Shasqi's most recent funding round was for $1.9M (USD) in December 2021.

How much has Shasqi raised to-date?

As of Dec 8, 2021, Shasqi has raised a total of $65.4M (USD).

How many employees does Shasqi have?

Shasqi has 24 employees as of Feb 4, 2024.

Shasqi - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cancer Therapeutics
Tags
  • Biotech
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified